Previous studies has shown the importance of sensitivity to first-line chemotherapy and performance status (PS) predicting the survival of recurrent small-cell lung carcinoma patients. However, the selection of stratified clinical factors are various in each clinical trials. The aim of this retrospective study was to evaluate pretreatment clinical parameters including laboratory data at recurrence as prognostic factors.Methods
From January 2003 to December 2010, consecutive recurrent small-cell lung cancer patients after receiving first-line chemotherapy were included in this retrospective study.Results
Fifty-eight patients were enrolled: 11 were female and 47 were male. The median age was 68.5 (38–76). Twenty-six patients (45%) were chemotherapy sensitive relapse, defined as relapse at an interval of >90 days after the completion of first-line chemotherapy. Eastern Cooperative Oncology PS at relapse was 0–1 and 2–3 in 81 and 19% of patients, respectively. In addition to both sensitivity to first-line chemotherapy and PS, multivariate analysis identified LDH and disease stage at recurrence as the independent prognostic factors.Conclusion
In this retrospective study, serum LDH is independent prognostic factors as well as sensitivity to first-line chemotherapy, PS and disease extent at recurrence. Serum LDH levels could be prognostic factors in recurrent small-cell lung cancer patients after receiving first-line chemotherapy.